What is the characteristic immunophenotypic profile of Chronic Lymphocytic Leukemia (CLL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Immunophenotypic Profile of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is commonly positive for CD5, CD19, CD20, and CD23, making option D the correct answer. 1

Characteristic Immunophenotype of CLL

CLL cells have a distinctive immunophenotypic profile that helps differentiate it from other lymphoproliferative disorders:

  • Core markers: CD5+, CD19+, CD20+ (dim), CD23+ 1
  • Additional markers: CD43+/-, CD200+, CD79b (dim/low) 1, 2
  • Surface immunoglobulin: Characteristically dim 1, 3
  • Light chain restriction: Either kappa or lambda 1

Key Distinguishing Features

  • CD20 expression is typically dim compared to normal B cells 1, 2
  • Surface immunoglobulin levels are characteristically low 1
  • CD5 positivity (a T-cell antigen aberrantly expressed on CLL B-cells) 3

Ruling Out Other Options

  • Option A (prolymphocytes >55%): Incorrect. In CLL, prolymphocytes may be present but must not exceed 55% of lymphocytes. When prolymphocytes exceed 55%, the diagnosis shifts to prolymphocytic leukemia, not CLL. 1

  • Option B (positive TRAP stains): Incorrect. Tartrate-resistant acid phosphatase (TRAP) staining is typically associated with hairy cell leukemia, not CLL. 1

  • Option C (diagnosis only by bone marrow examination): Incorrect. CLL diagnosis is usually possible by immunophenotyping of peripheral blood alone. Bone marrow biopsy is generally not required for diagnosis. 1

Diagnostic Criteria for CLL

For a definitive diagnosis of CLL, the following criteria must be met:

  • Presence of ≥5000 monoclonal B lymphocytes/μL in peripheral blood 1
  • Clonality confirmed by flow cytometry 1
  • Characteristic morphology: small, mature-appearing lymphocytes with narrow cytoplasmic border and dense nucleus 1

Differential Diagnosis

It's important to distinguish CLL from other CD5+ B-cell lymphoproliferative disorders:

  • Mantle cell lymphoma: Also CD5+, but typically CD23-, with t(11;14) translocation and cyclin D1 expression 1
  • Marginal zone lymphoma: Typically CD5-, CD23-, CD43 low 1
  • Small lymphocytic lymphoma (SLL): Same immunophenotype as CLL but <5000 B lymphocytes/μL with lymphadenopathy/splenomegaly 1

Clinical Implications

The immunophenotypic profile of CLL not only confirms diagnosis but also has prognostic implications:

  • Flow cytometry is essential for establishing diagnosis and monitoring disease 2
  • Additional genetic testing (FISH for del(11q), del(13q), trisomy 12, del(17p)) provides important prognostic information 1
  • IGHV mutation status should be determined before first treatment 4

The characteristic immunophenotype of CD5+, CD19+, CD20+ (dim), and CD23+ is a cornerstone for CLL diagnosis and helps distinguish it from other lymphoproliferative disorders.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.

Methods in molecular biology (Clifton, N.J.), 2019

Guideline

Diagnosis of Mature B-Cell Neoplasms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.